1-3 of 3
Marco L. Davila
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality

Shernan G. Holtan, Constanza Savid-Frontera, Kelly Walton, Anne A. Eaton, Connor Demorest, Andrea Hoeschen, Ling Zhang, Kayla Reid, Tony Kurian, Zena Sayegh, Estefania Julia, Joseph Maakaron, Veronika Bachanova, Najla El Jurdi, Margaret L. MacMillan, Daniel J. Weisdorf, Martin Felices, Jeffrey S. Miller, Bruce R. Blazar, Marco L. Davila, Brian C. Betts
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1114–1124.
https://doi.org/10.1158/1078-0432.CCR-22-2837
Published: 14 March 2023
View article titled, Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
Open the PDF for Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality in another window
Includes: Supplementary data
Journal Articles

Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Joseph Pidala, Kelly Walton, Hany Elmariah, Jongphil Kim, Asmita Mishra, Nelli Bejanyan, Taiga Nishihori, Farhad Khimani, Lia Perez, Rawan G. Faramand, Marco L. Davila, Michael L. Nieder, Elizabeth M. Sagatys, Shernan G. Holtan, Nicholas J. Lawrence, Harshani R. Lawrence, Bruce R. Blazar, Claudio Anasetti, Said M. Sebti, Brian C. Betts
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (10): 2712–2722.
https://doi.org/10.1158/1078-0432.CCR-20-4725
Published: 15 May 2021
View article titled, Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Open the PDF for Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results in another window
Includes: Supplementary data
Journal Articles

Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

Rawan Faramand, Michael Jain, Verena Staedtke, Hiroshi Kotani, Renyuan Bai, Kayla Reid, Sae Bom Lee, Kristen Spitler, Xuefeng Wang, Biwei Cao, Javier Pinilla, Aleksander Lazaryan, Farhad Khimani, Bijal Shah, Julio C. Chavez, Taiga Nishihori, Asmita Mishra, John Mullinax, Ricardo Gonzalez, Mohammad Hussaini, Marian Dam, Brigett D. Brandjes, Christina A. Bachmeier, Claudio Anasetti, Frederick L. Locke, Marco L. Davila
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (18): 4823–4831.
https://doi.org/10.1158/1078-0432.CCR-20-1434
Published: 15 September 2020
View article titled, Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel
Open the PDF for Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel in another window
Includes: Supplementary data